Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mipomersen in severe hypercholesterolemia not on apheresis
2008-006020-53Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2009
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Mipomersen 200 mg weekly with Placebo weekly (2 arms). Primary endpoint: Percent change in LDL-C from baseline. Started Feb 2009; status: completed.
02
Drugs
mipomersen
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2008-006020-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006020-53.